• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arvinas, Inc. - Common Stock (NQ:ARVN)

    7.450 -0.060 (-0.80%)
    Streaming Delayed Price Updated: 9:56 AM EDT, Sep 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 37,671
    Open 7.490
    Bid (Size) 7.440 (600)
    Ask (Size) 7.500 (200)
    Prev. Close 7.510
    Today's Range 7.360 - 7.500
    52wk Range 6.970 - 14.51
    Shares Outstanding 63,500,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    Arvinas to Participate in Upcoming Investor Conferences
    From Arvinas Inc.
    Via GlobeNewswire

    Performance

    YTD
    -35.0%
    -35.0%
    1 Month
    -19.0%
    -19.0%
    3 Month
    -10.1%
    -10.1%
    6 Month
    -26.8%
    -26.8%
    1 Year
    -12.7%
    -12.7%

    More News

    Read More
    News headline image
    Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    Arvinas (ARVN) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    Arvinas (NASDAQ:ARVN) Q1 2026 Results: First-Ever PROTAC Approval Offsets Revenue Miss ↗
    Via Chartmill
    Arvinas Inc (NASDAQ:ARVN) Stock Plummets After Q4 2025 Earnings and Revenue Miss Estimates ↗
    Via Chartmill
    News headline image
    Arvinas Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Transcript: Arvinas Q2 2026 Earnings Conference Call ↗
    Via Benzinga
    Topics Earnings
    News headline image
    Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data ↗
    Via MarketBeat
    News headline image
    Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    Arvinas to Present at Jefferies Global Healthcare Conference
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    Arvinas Employees Give Back During Company-wide Impact Day
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    These Analysts Increase Their Forecasts On Arvinas After Q1 Results ↗
    Via Benzinga
    News headline image
    Arvinas Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    Arvinas (ARVN) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    From Arvinas Inc.
    Via GlobeNewswire
    News headline image
    Arvinas to Participate in Upcoming Investor Conferences
    From Arvinas Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Arvinas, Inc. - Common Stock publicly traded?
    Yes, Arvinas, Inc. - Common Stock is publicly traded.
    What exchange does Arvinas, Inc. - Common Stock trade on?
    Arvinas, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Arvinas, Inc. - Common Stock?
    The ticker symbol for Arvinas, Inc. - Common Stock is ARVN on the Nasdaq Stock Market
    What is the current price of Arvinas, Inc. - Common Stock?
    The current price of Arvinas, Inc. - Common Stock is 7.450
    When was Arvinas, Inc. - Common Stock last traded?
    The last trade of Arvinas, Inc. - Common Stock was at 09/29/26 09:56 AM ET
    What is the market capitalization of Arvinas, Inc. - Common Stock?
    The market capitalization of Arvinas, Inc. - Common Stock is 473.07M
    How many shares of Arvinas, Inc. - Common Stock are outstanding?
    Arvinas, Inc. - Common Stock has 473M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.